Biodistribution, pharmacokinetics, and efficacy of prostate-cancer-targeted HPMA copolymer/DTX conjugates are evaluated in nude mice bearing prostate cancer C4-2 xenografts. PSMA-specific monoclonal antibodies 3F/11 are used as the targeting moiety. Control conjugates tumor accumulation to total background organs (heart, lung, kidney, liver, spleen and blood) accumulation increase substantially with time for the targeted conjugate, and the ratio at 48 h is 7-fold higher than that at 6 h. Preliminary evaluation of the efficacy of the conjugates in vivo show tumor growth inhibition for all HPMA copolymer/DTX conjugates.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605348 | PMC |
| http://dx.doi.org/10.1002/mabi.201100340 | DOI Listing |
Publication Analysis
Top Keywords
hpma copolymer/dtx
8
copolymer/dtx conjugates
8
conjugates
5
prostate-cancer-targeted n-2-hydroxypropylmethacrylamide
4
n-2-hydroxypropylmethacrylamide copolymer/docetaxel
4
copolymer/docetaxel conjugates
4
conjugates biodistribution
4
biodistribution pharmacokinetics
4
pharmacokinetics efficacy
4
efficacy prostate-cancer-targeted
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!